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Abstract
Background: In British Columbia, Canada, methadone maintenance treatment formulation transitioned from the
oral liquid compound Tang™-flavoured methadone to the ten-times more concentrated cherry-flavoured
Methadose™ in February 2014. We quantitatively describe perceptions and reported consequences among a sample
of patients on methadone maintenance treatment following this transition.
Methods: A province-wide survey was used. Bivariable analyses utilized independent samples t-tests, Phi
associations, and Chi-square tests. Multivariable logistic regression analyses evaluated factors related to
dependent variables – namely, increases in dose, pain, dope sickness, and the need to supplement with
additional opioids.
Results: Four hundred five methadone maintenance treatment patients from fifty harm reduction sites across British
Columbia reported transitioning to Methadose™ in February 2014. The majority (n = 258; 73.1 %) heard about the
formulation change from their methadone provider or pharmacist. Adjusted models show worse taste was positively
associated with reporting an increasing dose (OR = 2.46; CI:1.31–4.61), feeling more dope sick (OR = 3.39; CI:1.88–6.12),
and worsening pain (OR = 4.65; CI:2.45–8.80). Feeling more dope sick was positively associated with dose increase (OR
= 2.24; CI:1.37–3.66), and supplementing with opioids (OR = 8.81; CI:5.16–15.05).
Conclusions: Methadone maintenance treatment policy changes in British Columbia affect a structurally vulnerable
population who may be less able to cope with transitions and loss of autonomy. There may be a psychosocial
component contributing to the perception of Methadose™ tasting worse, and increased dope sickness, pain, and dose.
Our study shows the pronounced negative impacts medication changes can have on patients without informed,
coordinated efforts. We stress the need to engage all stakeholders allowing for communication about the reasons, risks
and consequences of medication policy changes and provision of additional psychosocial support.
Keywords: Methadone, Methadose, Opioid substitution therapy, Medication formulation change, People who use
drugs, Change intolerance, Policy change
Background
Methadone is a long-acting synthetic mu-opioid agonist
with unique dual opioid receptor agonist and non-
selective N-methyl-D-aspartate (NMDA) receptor antag-
onist abilities [1]. Methadone has been available for
more than 50 years and is viewed as an efficacious and
safe agent for the treatment of chronic pain and opioid
addiction [1–3]. Taken orally once daily, methadone is
used to initiate and maintain abstinence from illicit opi-
oid use by relieving craving, suppressing opioid abstin-
ence syndrome, and attenuating the euphoric effects of
illicit opioid use [4, 5]. Methadone maintenance treat-
ment (MMT) is an evidence-based harm reduction inter-
vention shown to decrease injection drug use, and
thereby reduces the impact of blood-borne illnesses,
such as HIV and hepatitis C [6, 7], and reduces morbid-
ity, and mortality among people who use drugs (PWUD)
[8]. When patients with opioid dependence initiate
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MMT, methadone is initially administered on a daily
basis under the supervision of a pharmacist. Doses are
titrated by the prescribing physician, and split doses are
considered in symptomatic patients who demonstrate
rapid metabolism or who are pregnant [9]. Patients who
demonstrate biopsychosocial stability may be granted
“carry” privileges and receive doses of methadone for
home administration [10].
Periodic transitions in drug dispensing and prescribing
policies are necessary due to developments in pharmaco-
logical research or guideline shifts. In British Columbia
(BC), Canada, several bodies regulate the dispensation of
methadone and coordinate to implement policy or pre-
scription changes: the BC Ministry of Health, a branch
of the provincial government that leads policy changes
regarding methadone; BC PharmaCare, a public entity
covers the cost of prescription drugs, including metha-
done, for low-income individuals [11]; the College of
Physicians and Surgeons of BC, which grants physicians
the authority to prescribe methadone [12]; and the
BC College of Pharmacists who standardize the train-
ing of pharmacists and dispensation of methadone in
the province [13].
In 2014, these regulatory bodies made the decision to
transition from the previous Tang™-flavoured (orange
type flavor) 1 mg/mL pharmacist-compounded metha-
done formulation to methadone hydrochloride 10 mg/
mL cherry-flavoured oral liquid (Methadose™) [10]. BC
was the second province in Canada to implement the
transition to Methadose™; 14,662 patients were regis-
tered in the methadone treatment program at the time
[14]. The decision was based on several advantages of
Methadose™, including a longer shelf life (up to four
years if unopened), elimination of the need for refriger-
ation, improved quality control, and consistent dosing,
which is possible mainly because Methadose™ is a solu-
tion prepared by the manufacturer rather than mixed or
diluted by a pharmacist [10]. The new formulation is
cited as hypertonic and painful to inject, a feature
that may deter opioid abuse and medication diversion
[10, 15]. In addition to formulation changes, a new
policy was introduced by the College of Physicians
and Surgeons of BC restricting pharmacies to provide
home deliveries “under extraordinary circumstances,”
requiring written authorization from the prescribing
physician [10].
The transition to the methadone formulation Metha-
dose™ posed several major public health concerns. First,
methadone formulation changes may cause stress and in-
stability in previously stable patients [16]. Such changes
may result in patients discontinuing MMT and/or supple-
menting with other illegally obtained drugs [16, 17].
People who are prescribed MMT often belong to a vulner-
able population that may experience difficulties with drug
policy transitions and consequently, are less tolerant to
changes in methadone prescribing or dispensing practices
[16, 17]. Secondly, accidental overdoses during the transi-
tion period were a concern. Methadose™ is ten times more
concentrated by volume compared to the previously com-
pounded methadone, and is dispensed undiluted. Hence,
there is potential for prescribing and dispensing errors
during the transition period, further increasing overdose
risk. As well, given that a smaller volume is dispensed, it
may make it more difficult to titrate doses to patients.
During the methadone transition period in BC, phar-
macists were asked to educate patients about safety con-
cerns, including increased risk of overdose, education on
take-home naloxone (an opioid antagonist), and appro-
priate security and storage [10]. The College of Physi-
cians and Surgeons of BC in collaboration with the
College of Pharmacist of BC provided information and
training to physicians and pharmacists in the province;
the colleges worked with people prescribed methadone
to produce patient information resources [12]. Public
health campaigns, such as posters, were distributed to
harm reduction sites and media releases were initiated
in BC to communicate the changes in appearance and
concentration of the new methadone formulation [15].
PWUD who engaged with harm reduction sites and
community advocacy groups expressed concerns regard-
ing the lack of awareness and involvement in the transi-
tion process. Patients on MMT reported dissatisfaction
with Methadose™ and disruptions in treatment, which
informed the intent and need to conduct a quantitative
province-wide survey. Our study seeks to understand ex-
periences reported by MMT patients after the transition
to the new methadone formulation, Methadose™. We
compare the perceptions of the new Methadose™ to the
previous compounded methadone formulation through
several variables, including satisfaction and efficacy mea-




Four focus groups (n = 32) were undertaken with PWUD
in Vancouver in the six weeks following the transition to
Methadose™ to explore concerns about the methadone
formulation change and inform the quantitative survey
questions. The results of this qualitative study have been
presented elsewhere [18]. Drug user organizations in-
cluding the Vancouver Area Network of Drug Users and
BC Association of People on Methadone were actively
engaged and provided input regarding content and
wording of the draft questions which were incorporated
into the final survey. The final survey consisted of twelve
methadone-specific questions, including: How do you
find the taste of the new cherry Methadose™ compared
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to the orange methadone? Did your dose change with
the new cherry Methadose™ compared to the orange
methadone? Do you feel you need to take additional opi-
oids with the new cherry Methadose™ compared to the
orange methadone? In general, do you wake up feeling
dope sick on the new cherry Methadose™ compared to
the orange methadone? In general, how do you find the
new cherry Methadose™ addresses your pain needs com-
pared to the orange methadone?
The main variables of interest were subjective changes
in dose, pain, taste, dope sickness, and the need to supple-
ment with additional opioids. We also collected informa-
tion on age, gender, ethnicity, housing status, geographic
location, health authority, and how the participant heard
about the Methadose™ changes (i.e. methadone health care
provider or non-health care provider). Participants who
reported carries were also asked how they stored
Methadose™.
Recruitment and sample
An annual survey was introduced in 2012 to obtain in-
formation about drug use and related harms, and to
evaluate the harm reduction supply distribution program
throughout BC [19]. A two-stage enrollment process
was used: harm reduction distribution sites with suffi-
cient clients and resources were identified and invited to
participate. In 2014, sites were requested to recruit a
maximum of 40 PWUD aged 19 years and older over
eight weeks in the summer (i.e. four to six months after
the Methadose™ transition occurred); Vancouver Coastal
Health Authority was intentionally oversampled due to
the high density population of MMT patients in this re-
gion. Sites were provided with $5 per survey to defray
the costs of administering the survey and/or for partici-
pant incentives as the site determined most appropriate.
Survey responses were entered into Fluid Surveys, an
online database. Details of these survey methods have
been described previously [19].
Statistical analysis
Statistical analysis was performed with SPSS 21.0 and R
2.3.1. Bivariable evaluations of the data were conducted
through independent samples t tests for continuous vari-
ables, and by Chi-square (x2) tests and calculating the
Phi coefficient of association to determine the relation-
ship between binary variables. Multivariable logistic re-
gression analyses were performed to evaluate factors
related to dependent variables – namely: dose, pain,
dope sickness, and the need to supplement with add-
itional opioids. First, independent variables were consid-
ered in a forward stepwise variable selection procedure.
The criterion for entry in the stepwise procedure was a
significance level of P less than 0.05. Two explanatory
variables, pain and dope sickness, were not included as
predictors in any same model. The rationale for this was
threefold. First, the bivariable analysis revealed a rela-
tively strong association (Phi = 0.46), indicating that they
may be describing the same effects, as pain may be a
symptom of dope sickness. Second, the addition of pain
increased the standard error of the beta coefficient for
dope sick, indicative of a collinear variable. Finally, add-
ing pain into the models in addition to dope sickness de-
creased the overall predictive power of the model, as
indicated in the Hosmer Lemeshow tests. Dope sickness
was retained in the final model of supplement and dose
increase since the predictive power was higher than
the model that included pain instead. The Hosmer
Lemeshow chi-square tests (df = 8) for all models sug-
gested they were a good fit to the data as p = 0.29–
0.89 (>0.05). Nagelkerke R2 for models ranged from
0.10 to 0.60 indicating models were able to explain
between 10–60 % of variability in the data. Although
age and gender did not have a significant effect on
any dependent variable, both were force entered into
the models to account for any influence of demo-
graphics. For responses where participants could
qualitatively enter an “other” description, items were
categorized and frequencies were calculated to de-
scribe patterns.
Results
Fifty harm reduction distribution sites across the prov-
ince returned 1322 completed surveys. Of these, 405 re-
spondents reported being on MMT at the time of
transition to Methadose™. The survey provided a sample
of MMT patients from all five geographic health regions
across BC. The proportion of respondents from each re-
gional health authority that were enrolled in an MMT
program varied from 39.5 % in Vancouver Coastal
Health to 19.0 % in Fraser Health Authority. Eighty-nine
percent of participants in this sample reported polysub-
stance use in the past 7 days. The socio-demographic
characteristics of the 405 respondents in the MMT pro-
gram at the time of transition are shown in Table 1.
The majority (80.9 %) of participants reported a worse
taste with the new Methadose™ cherry-flavoured syrup
compared to the previous Tang™-flavoured methadone
(Table 2). A third of respondents reported increasing
their dose of Methadose™, while over half of respondents
reported having worse pain, feeling more dope sick, and
supplementing their methadone with other opioids.
Table 3 describes variables assessing MMT outcomes.
The majority (n = 258; 73.1 %) of participants heard
about the changes in their MMT from their health
care provider or methadone pharmacist. Thirty-two
(16.1 %) patients with methadone carries (n = 199)
stored their methadone in a locked box. Of those
who provided a reason for increasing their methadone
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dose (n = 76), three quarters reported it was to man-
age symptoms; 46.1 % to avoid feeling dope sick and
28.9 % to relieve pain.
In the bivariable analyses, outcome and explanatory
variables of interest were all significantly and strongly
associated as indicated in the Chi-square tests and Phi
association measure (Table 3). In the multivariable logis-
tic regression analysis (Table 4), reporting worse taste
was independently associated with increased dose (OR =
2.46; CI: 1.31–4.61), more dope sick (OR = 3.39; CI:
1.88–6.12) and worse pain (OR = 4.65; CI: 2.45–8.80),
while being more dope sick was found to be positively
associated with the odds of increasing dose (OR = 2.24;
CI: 1.37–3.66), and supplementing with opioids (OR =
8.81; 5.16–15.05).
Discussion
The goal of this study was to explore the perceptions of
how persons enrolled in MMT in BC were affected by
the transition to Methadose™. Our findings revealed
large proportions of participants reported worse taste,
the need to increase methadone dose, and increased
withdrawal and pain symptoms. Worse taste was signifi-
cantly correlated with reported lack of effectiveness and
deterioration of symptoms across multiple parameters,
as demonstrated by more withdrawal symptoms, pain
and need to increase dose. These associations were not
significantly related to how patients heard about the
formulation change, geographic region, or other sociode-
mographic factors. Overall, our findings of increased
pain, withdrawal symptoms, and need to increase metha-
done dose following the formulation change to Metha-
dose™ have implications for the wellbeing of MMT
patients in BC that must be considered.
Previous studies support our findings that medication
transition periods can have pronounced bio-psychosocial
impacts on patients. In the United Kingdom, change in
methadone formulation in 1992 was correlated with an
Table 1 Sociodemographics of a sample of methadone
maintenance treatment patients following a methadone
formulation change in British Columbia (n = 405)
Number Percent




Vancouver Coastal 232 57.3
Vancouver Island 67 16.5
Ethnicity (n = 393)
Aboriginal 114 29.0
Non-Aboriginal 279 71.0




Housing (n = 390)
Stable (housed > =3 months) 305 78.2
Unstable (<3 months or homeless) 85 21.8
Age in years (n = 403) Mean (SD) Range
42 (10.3) 19 – 71
Table 2 Perceptions and outcomes of patients on methadone
maintenance treatment following a formulation change
N (%)
How heard about the change (n = 353)
Health care provider or methadone pharmacist 258 (73.1)
Non methadone service provider 33 (9.3)
Family or friend 26 (7.4)
Newspaper or poster 36 (10.2)
Of those with carries (n = 199)
Does not store methadone in locked box 167 (83.9)
Does store methadone in locked box 32 (16.1)
Splitting doses (n = 293)
No change 269 (91.8)
Started splitting 21 (7.2)
Stopped splitting 3 (1.0)
Reason dose increased (n = 76)
To avoid feeling dope sick 35 (46.1)
To relieve pain 22 (28.9)
To avoid using other opioids 19 (25.0)
Reason for supplementing (n = 178)
To avoid feeling dope sick 92 (51.7)
To relieve pain 86 (48.3)
Taste difference (n = 371)
Same or better taste 71 (19.1)
Worse taste 300 (80.9)
Dose changes (n = 320)
Lowered or same dose 213 (66.6)
Increased dose 107 (33.4)
Dope sick changes (n = 358)
Same or less dope sick 156 (43.6)
More dope sick 202 (56.4)
Pain changes (n = 358)
Same or better pain 165 (46.1)
Worse pain 193 (53.9)
Supplements with opioids (n = 360)
No supplementing with opioids 179 (49.7)
Yes supplementing with opioids 181 (50.3)
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increase use of non-prescription opioids, decline in so-
cial stability, and an increase in pharmacy break-ins [20].
A clinical study conducted by Soyka and Zingg in 2009
found the transfer from racemic methadone to (R)-
methadone decreased withdrawal symptoms, cravings,
and supplementing with additional drugs [21]. In our
study, over half of participants reported supplementing
with other drugs following the transition to Methadose™.
Methadone diversion and its illicit use are not uncom-
mon; the 2014 survey of clients at harm reduction
supply distribution sites in BC found that 8 % of re-
spondents accessed methadone without a prescription
(unpublished BCCDC data). Diversion in medication
compliance has been critical in subsequent injection
drug use, crime, and morbidity and mortality rates
[22, 23]; hence, any instability in MMT leading to a
rebound in illicit drug use may result in possible decline
in social function and worse health outcomes in BC.
Silver and Shaffer (1997) found patients could be more
intolerant to methadone formulation changes than
others (coined ‘change intolerance’) [24]. In their study
of 177 MMT patients, researchers found gender, treat-
ment history, and previous methadone abuse predicted
change intolerance. Gourevitch et al. provides further
evidence demonstrating that change intolerance to dif-
ferent methadone formulations is related to psychosocial
stressors rather than having a pharmacodynamic basis
[17]. In a small double-blind crossover trial of three
methadone formulations they demonstrated self-
reported withdrawal symptoms did not correlate with
plasma methadone levels [17]. The effect of taste on pa-
tients’ perception of pharmacological efficacy and side
effects is not well studied. A randomized control trial
conducted by Farr (1986) showed that medication taste
affected participants’ perceptions [25]. In this study, bit-
ter tasting zinc gluconate lozenges were perceived to
have more negative side effects than the tasteless pla-
cebo tablets. This effect diminished when taste-matching
placebos were used [25]. In France, where the capsule
formulation of MMT recently became available in
addition to the syrup formulation, two recent studies
showed the potential superiority of the dry (capsule)
MMT formulation [18, 26]. Boucherie et al. (2015) dem-
onstrated that there was a rise in capsule MMT users in
a five year period with a corresponding drop in preva-
lence of individuals using the syrup formulation [26],
and Eiden et al. (2013) described 80 % of patients experi-
enced negative side effects from use of the syrup MMT
formulation [18]. In light of the large proportion of
MMT patients in our study who reported worse taste
and its relation to negative outcomes, consideration of
other formulations of methadone including the capsule
Table 3 Bivariable associations between taste, dose increased, supplements, pain, and dope sickness following a methadone
formulation change
Taste worsened Dose increased Began supplementing with opioids More dope sick
X2 Phi X2 Phi X2 Phi X2 Phi
Dose increased 9.93** 0.20**
Began supplementing with opioids 3.99* 0.11* 21.50** 0.27**
More dope sick 22.52** 0.25** 13.70** 0.20** 70.63** 0.46**
More pain 22.23** 0.27** 13.06** 0.21** 29.43** 0.30** 77.28** 0.46**
*p < 0.05, **p < 0.01
degrees of freedom for Chi-square (X2) tests = 1
Table 4 Adjusted odds ratios (OR) with 95 % confidence intervals (CI) and goodness of fit for taste and more dope sick related to odds
of dose increase, supplements with additional opioids, more dope sick, and more pain following methadone formulation change
Wald OR* 95 % CI** Hosmer Lemeshow Test Nagelkerke R2
Dose Increased
Taste 7.79 2.46 1.31–4.61 0.89 0.37
More dope sick 10.28 2.24 1.37–3.66
Supplements
More dope sick 63.89 8.81 5.16–15.05 0.29 0.60
More dope sick
Taste 11.91 3.39 1.88–6.12 0.30 0.11
More pain
Taste 22.06 4.65 2.45–8.80 0.83 0.10
*OR adjusted for age, gender, and indicated covariates
**95 % CI based on Wald chi-square tests with df = 1
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form, may be warranted. However, some literature has
highlighted that non-syrup forms of MMT may increase
diversion and misuse liability [18].
These findings are corroborated by a recent qualitative
study conducted by McNeil et al. (2015) who inter-
viewed 34 MMT patients in the Vancouver region; 31
who had transitioned to MethadoseTM at the time of
interview [16]. This study supports the notion that the
methadone formulation transition in BC produced con-
siderable negative health and social impacts on patients
and demonstrated that these effects were exacerbated by
the structural vulnerability that patients on MMT are
subjected to [16]. They also suggest real or perceived
withdrawal symptoms might have a psychological com-
ponent, as in our study, which strongly suggests percep-
tions of changes in taste contribute to withdrawal
symptoms, pain, and need to increase dose. Although we
anticipated similar findings, our study had a number of
strengths and adds to the literature. We had quantitative
responses from over 400 people throughout the province
and, thus, our results were not limited to the Vancouver
area. While methadone formulation changes have oc-
curred in other provinces in Canada (i.e. Alberta,
Ontario), there remains a lack of evaluation data of the
impact and differences of the implementation of these
policies.
These studies and ours underscore the importance of
recognizing that many persons participating in MMT
belong to a particularly vulnerable population who are
often victim to structural discrimination, which may
make them less able to cope with imposed medication
changes and loss of autonomy [25]. Trujols et al. (2011)
argue much of the satisfaction with MMT comes from
patients who perceive themselves as participating to
some extent in treatment decisions [27]. The impact of
the transition to Methadose™ in BC among MMT pa-
tients may be further exacerbated by the change in home
delivery policy further adding to the instability and dis-
satisfaction to the program. The capacity for agency and
a flexible interim period appear to be important factors
in the stability of medication transitions. There is evi-
dence that patients are more satisfied with their MMT
programs when they perceive themselves as participating
in treatment decision-making [27]. Another study sug-
gested that although there may be some transitional in-
stabilities encountered after methadone formulation
changes, they could be further mitigated by providing
patients with a longer transition period as well as a
choice of the transitional process [28].
One strategy to mitigate this impact that could be in-
corporated during medication formulation changes, is
involving and consulting the community affected in the
development and implementation of new regulatory pol-
icies. El Ansari and Phillips (2004) found that a low
amount of involvement with the community is associ-
ated with decreased costs and increased satisfaction with
policies [29]. In BC, the College of Pharmacists, College
of Physicians and Surgeons and Ministry of Health met
with representatives from the Vancouver Area Network
of Drug Users and BC Association of People on Metha-
done on three occasions over ten months prior to the
change to Methadose™ (Personal communication Solven
S., 2015). During this time patient groups provided feed-
back regarding the dispensing standards for MMT that
resulted in several changes and helped to produce com-
munication materials (i.e. “Think before you drink” cam-
paign) [30].
Despite a concerted effort by the College of Pharmacists
of BC to engage with people on methadone, our study
found significant negative perceptions of the methadone
formulation change in the province. It is interesting to
note that our results showed nearly three-quarters heard
about the methadone formulation transition from their
methadone-prescribing physician or pharmacist, who
could be a useful avenue for the dissemination of educa-
tional resources. However, the remaining one-quarter of
participants could have benefited from greater awareness
and public education campaigns during the transition
period. Patients may benefit from longer and more flexible
transitional timeline of several months, rather than weeks,
when the old formulation may be accessible during the
introduction of the new formulation. During this time, pa-
tients could be monitored closely for changes in pain and
dope sickness. Although patients may be more accepting
with a longer and more flexible transition period, the Col-
lege of Pharmacists of BC believed a shorter transition
period would minimize the chance of error with the two
different strengths, and therefore decided against an in-
creased transition period(Personal communication Solven
S., 2015). Lastly, it may have been helpful to introduce
different formulation options for patients; similar to
Alberta and Ontario, Methadose™ may be better tolerated
(particularly taste) if MMT patients were given the option
to have unflavored Methadose™ or be able to dilute in a
Tang™-flavored drink which would maintain consistency
with previous volume and flavor [31, 32].
While our study highlights some important findings
that may have policy implications, several limitations
must be considered. First, we recruited and sampled
people who access harm reduction sites for supplies
across BC, signifying that many of our survey partici-
pants may use illicit drugs in addition to their MMT.
These patients may represent a structurally vulnerable
population [16]; as such, these findings may not be
generalizable to all MMT patients. However, it is im-
portant to understand the challenges of MMT for these
individuals and reduce their heightened barriers for ac-
cess [33]. Although our study was administered in all
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five regional health authorities at 50 harm reduction
sites across BC, access to MMT varies across regions.
Regions where patients have one source of MMT may
be more accepting of changes as they are not accus-
tomed to having a choice of MMT; however, our find-
ings were not significantly different across regions. As
this study was a cross-sectional design after the change
occurred, satisfaction with MMT was not assessed prior
to the change. Future research may benefit from measur-
ing dose and satisfaction with MMT longitudinally, cap-
turing both before and after measures. This study did
not examine whether negative experiences following the
formulation change impacted continuation on MMT,
which could be an area for future research. Finally,
multiple bivariate analyses were conducted with many
variables serving as both explanatory and outcome
variables. With multiple analyses, we acknowledge the
consequent risk of Type I error that may be inflated
with this type of analysis.
Conclusion
In conclusion, we characterized several negative percep-
tions and outcomes among a sample of MMT patients fol-
lowing a province-wide methadone formulation change to
Methadose™ in BC, Canada. These findings highlight the
structural vulnerability PWUD and MMT patients face,
and point to the importance of involving all stakeholders
policy decision-making. We urge policy makers to con-
sider a more engaging and transparent approach when
working with structurally vulnerable populations, includ-
ing people with a history of substance misuse, incarcer-
ation and mental health illness, and homelessness.
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